{"brief_title": "A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas", "brief_summary": "The purpose of this study is to find out about the safety of adding the investigational drug motexafin gadolinium to a standard course of chemotherapy with temozolomide for patients with malignant glioma. Secondly, the study will determine how many patients will respond to this treatment.", "condition": ["Glioma", "Glioblastoma", "Astrocytoma", "Oligodendroglioma", "Brain Neoplasm"], "intervention_type": ["Drug"], "intervention_name": ["Motexafin Gadolinium Injection"], "criteria": "Inclusion Criteria: - At least 18 years old - Histologically confirmed diagnosis of malignant gliomas that requires systemic antineoplastic treatment. Malignant glioma is defined as any of the following: Glioblastoma multiforme (GBM); Anaplastic astrocytoma (AA); Anaplastic oligodendroglioma; Anaplastic mixed glioma; Glioma not otherwise specified (except low-grade glioma) - ECOG performance status score of 0, 1, or 2 - Each patient must sign a study-specific informed consent form Exclusion Criteria: Laboratory values of: - Absolute neutrophil count < 2000/\u00b5L - Platelet count < 100,000/\u00b5L - AST or ALT > 2 x the upper limit of normal (ULN) - Alkaline phosphatase > 5 x ULN - Bilirubin > 2 x ULN - Creatinine > 2.0 mg/\u00b5L and - Plan to use any additional cancer therapy (e.g., systemic, radiation, surgery) during the study period - Women who are pregnant or lactating", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Glioma", "mesh_term": ["Glioblastoma", "Glioma", "Astrocytoma", "Oligodendroglioma", "Brain Neoplasms", "Temozolomide", "Motexafin gadolinium"], "id": "NCT00080054"}